NCT04250545 2025-11-25
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
3 trialsNCT02142803 2025-11-13
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02133183 2024-04-04
Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1 Terminated